Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce successful completion of the data lock for the pivotal Felix(TM) clinical trial. This marks a critical milestone in ensuring the accuracy and integrity of the trial data.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in precision diagnostics, is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys 2025 Healthcare Forum being held on 4 February 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) Managing Director Dr. Richard Lipscombe is Interviewed about the ProMarker Suite of Diagnostic Tests.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 December 2024.
Proteomics International Laboratories Ltd (ASX:PIQ) has published groundbreaking results demonstrating the unique OxiDx test for oxidative stress can identify muscle damage and assess recovery in elite marathon runners.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce the publication of new results in the journal Human Reproduction showing its PromarkerEndo blood test can diagnose all stages of endometriosis with high accuracy.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that its cash reserves have been further strengthened by the receipt of $2.16 million in research and development tax incentive for the 2023-24 financial year.
